478 related articles for article (PubMed ID: 34490728)
1. High SHP2 expression determines the efficacy of PD-1/PD-L1 inhibitors in advanced KRAS mutant non-small cell lung cancer.
Feng HB; Chen Y; Xie Z; Jiang J; Zhong YM; Guo WB; Yan WQ; Lv ZY; Lu DX; Liang HL; Xu FP; Yang JJ; Yang XN; Zhou Q; Zhang DK; Zhang Z; Chuai SK; Zhang HH; Wu YL; Zhang XC
Thorac Cancer; 2021 Oct; 12(19):2564-2573. PubMed ID: 34490728
[TBL] [Abstract][Full Text] [Related]
2. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation.
Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S
Front Immunol; 2022; 13():974581. PubMed ID: 36159860
[TBL] [Abstract][Full Text] [Related]
4. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.
Negrao MV; Skoulidis F; Montesion M; Schulze K; Bara I; Shen V; Xu H; Hu S; Sui D; Elamin YY; Le X; Goldberg ME; Murugesan K; Wu CJ; Zhang J; Barreto DS; Robichaux JP; Reuben A; Cascone T; Gay CM; Mitchell KG; Hong L; Rinsurongkawong W; Roth JA; Swisher SG; Lee J; Tsao A; Papadimitrakopoulou V; Gibbons DL; Glisson BS; Singal G; Miller VA; Alexander B; Frampton G; Albacker LA; Shames D; Zhang J; Heymach JV
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34376553
[TBL] [Abstract][Full Text] [Related]
5. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials.
Landre T; Justeau G; Assié JB; Chouahnia K; Davoine C; Taleb C; Chouaïd C; Duchemann B
Cancer Immunol Immunother; 2022 Mar; 71(3):719-726. PubMed ID: 34378081
[TBL] [Abstract][Full Text] [Related]
6. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
Shirasawa M; Yoshida T; Shimoda Y; Takayanagi D; Shiraishi K; Kubo T; Mitani S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Ichikawa H; Kohno T; Yamamoto N; Matsumoto S; Goto K; Watanabe SI; Ohe Y; Motoi N
J Thorac Oncol; 2021 Dec; 16(12):2078-2090. PubMed ID: 34419685
[TBL] [Abstract][Full Text] [Related]
7. Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy.
Wu F; Jiang T; Chen G; Huang Y; Zhou J; Lin L; Feng J; Wang Z; Shu Y; Shi J; Hu Y; Wang Q; Cheng Y; Chen J; Lin X; Wang Y; Huang J; Cui J; Cao L; Liu Y; Zhang Y; Pan Y; Zhao J; Wang L; Chang J; Chen Q; Ren X; Zhang W; Fan Y; He Z; Fang J; Gu K; Dong X; Zhang T; Shi W; Zou J; Bai X; Ren S; Zhou C;
Cancer Commun (Lond); 2022 Dec; 42(12):1331-1346. PubMed ID: 36331328
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRAS
Ricciuti B; Alessi JV; Elkrief A; Wang X; Cortellini A; Li YY; Vaz VR; Gupta H; Pecci F; Barrichello A; Lamberti G; Nguyen T; Lindsay J; Sharma B; Felt K; Rodig SJ; Nishino M; Sholl LM; Barbie DA; Negrao MV; Zhang J; Cherniack AD; Heymach JV; Meyerson M; Ambrogio C; Jänne PA; Arbour KC; Pinato DJ; Skoulidis F; Schoenfeld AJ; Awad MM; Luo J
Ann Oncol; 2022 Oct; 33(10):1029-1040. PubMed ID: 35872166
[TBL] [Abstract][Full Text] [Related]
9. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP).
Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF
Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125
[TBL] [Abstract][Full Text] [Related]
10. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
11. Subtyping of advanced lung cancer based on PD-L1 expression, tumor histopathology and mutation burden (EGFR and KRAS): a study from North India.
Kulshrestha R; Saxena H; Kumar R; Spalgais S; Mrigpuri P; Goel N; Menon B; Rani M; Mahor P; Bhutani I
Monaldi Arch Chest Dis; 2023 Feb; 93(4):. PubMed ID: 36723380
[TBL] [Abstract][Full Text] [Related]
12. Does Molecular Profiling of
Karim NA; Ullah A; Pathrose P; Fathallah H; Perry A; Morris JC; Wang J; Starnes SL
Curr Oncol; 2022 Jul; 29(7):4779-4790. PubMed ID: 35877239
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy of Immune Checkpoint Inhibitors vs. Chemotherapy for KRAS-Mutant or EGFR-Mutant Non-Small-Cell Lung Cancers: A Meta-Analysis Based on Randomized Controlled Trials.
Chen W; Li L; Cheng S; Yu J
Dis Markers; 2022; 2022():2631852. PubMed ID: 36061356
[TBL] [Abstract][Full Text] [Related]
14. Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.
Fu NJ; Xi RY; Shi XK; Li RZ; Zhang ZH; Li LY; Zhang GL; Wang F
Toxicol Appl Pharmacol; 2022 Apr; 441():115988. PubMed ID: 35307375
[TBL] [Abstract][Full Text] [Related]
15. Concurrent High PD-L1 Expression and CD8
Shimoda Y; Shibaki R; Yoshida T; Murakami S; Shirasawa M; Torasawa M; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Yamamoto N; Ohe Y; Motoi N
Clin Lung Cancer; 2022 Sep; 23(6):477-486. PubMed ID: 35644780
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in patients treated with frontline immune checkpoint inhibition (ICI) for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels.
Sun L; Handorf EA; Zhou Y; Borghaei H; Aggarwal C; Bauman J
Lung Cancer; 2024 Apr; 190():107510. PubMed ID: 38432028
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant).
Wu JJ; Lee PH; Zheng ZR; Huang YH; Tseng JS; Hsu KH; Yang TY; Yu SL; Chen KC; Chang GC
Medicine (Baltimore); 2022 Jun; 101(24):e29381. PubMed ID: 35713442
[TBL] [Abstract][Full Text] [Related]
18. Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report.
Fang C; Zhang C; Zhao WQ; Hu WW; Wu J; Ji M
BMC Med Genomics; 2019 Oct; 12(1):136. PubMed ID: 31619231
[TBL] [Abstract][Full Text] [Related]
19. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy.
Bodor JN; Bauman JR; Handorf EA; Ross EA; Clapper ML; Treat J
J Cancer Res Clin Oncol; 2023 May; 149(5):1755-1763. PubMed ID: 35708776
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of
Tønnesen EMT; Stougaard M; Meldgaard P; Lade-Keller J
J Clin Pathol; 2023 Dec; 77(1):54-60. PubMed ID: 36410939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
